- A large analysis found very high lipoprotein(a), or Lp(a), was linked with higher risk of major cardiovascular events.
- The strongest links were seen for stroke and cardiovascular death.
- Lp(a) is largely genetic and often missed because it is not part of standard cholesterol testing.
Many people know their cholesterol number.
Far fewer know their Lp(a).
That could matter because lipoprotein(a), often shortened to Lp(a), is an inherited cholesterol-related particle that can raise cardiovascular risk even when standard cholesterol results look acceptable.
A large analysis of more than 20,000 people found that very high Lp(a) levels were independently linked with greater risk of major cardiovascular events.
The researchers looked at participants from three major NIH trials: ACCORD, PEACE and SPRINT.
They measured Lp(a) in stored blood samples and followed cardiovascular outcomes.
An Lp(a) level of 175 nmol/L or above was associated with a higher risk of major cardiovascular events.
- Eye clinics could help catch dangerous blood pressure in people with diabetes
- Retatrutide improves blood sugar and weight loss in type 2 diabetes trial
It was also linked with higher risk of cardiovascular death and stroke.
Interestingly, it was not linked with a higher risk of heart attack in this analysis.
The association appeared stronger in people who already had heart disease than in those without existing disease.
This is clinically important because high Lp(a) is mostly genetic.
Lifestyle changes do not usually lower it dramatically.
But knowing someone has high Lp(a) can still change management.
It may justify more aggressive control of other modifiable risk factors such as LDL cholesterol, blood pressure, smoking, weight, glucose and kidney health.
For people with diabetes, the relevance is obvious.
Diabetes already increases cardiovascular risk.
- Delivered groceries improved blood sugar in people with type 2 diabetes
- Higher blood sugar linked to faster brain ageing
If someone also has high Lp(a), the hidden inherited risk may add another layer.
A standard lipid panel may not pick this up.
Lp(a) needs its own blood test.
The study does not mean everyone with high Lp(a) is destined to have a stroke or heart disease.
It means risk may be underestimated if Lp(a) is never measured.
New targeted treatments are also being developed, which makes identifying high-risk patients more useful.
For now, the practical message is simple.
If you have diabetes, early heart disease in the family or unexplained cardiovascular risk despite decent cholesterol numbers, it may be worth asking your clinician whether Lp(a) testing is appropriate.






